Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc.ABOS · Entity 6281 | CFO & Chief Business Officer | January 21, 2026 | January 23, 2026 |
| ELUTIA INC.ELUT · Entity 7342 | Director · 10% owner | May 29, 2025 | June 02, 2025 |
| Quantum-Si IncCAPA · Entity 6440 | Director · 10% owner | September 03, 2020 | September 03, 2020 |
| TELA Bio, Inc.TELA · Entity 7381 | Director | November 08, 2019 | November 14, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acumen Pharmaceuticals, Inc.
Report date January 21, 2026 · Filed January 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 304,924 |
Ending reported balance
After 2026-01-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-01-21 · Sale · Disposed 2,473 · Balance 306,611 F1: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024. F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7650 to $1.8700. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 2 · 2026-01-22 · Sale · Disposed 1,687 · Balance 304,924 F1: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024.
F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7650 to $1.8700. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
ELUTIA INC.
Report date May 29, 2025 · Filed June 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 · Expires 2035-05-29 | Direct | 60,339 |
Reported balance
After 2025-05-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-29 · Grant · Acquired 60,339 · Balance 60,339 F1: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continuing in service on the Issuer's board of directors through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continuing in service on the Issuer's board of directors through the applicable vesting date.
Quantum-Si Inc
Report date September 03, 2020 · Filed September 03, 2020
Jointly reported with HighCape Capital Acquisition LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-09-03 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-240283) (the "Registration Statement") and have no expiration date. The shares of Class B common stock beneficially owned by the Reporting Persons include up to 375,000 shares of Class B common stock subject to forfeiture to the Issuer depending on the extent to which the underwriters' over-allotment option is exercised in connection with the Issuer's initial public offering of units, as described in the Registration Statement. F2: HighCape Capital Acquisition LLC is the record holder of the securities reported herein. Matt Zuga is the sole manager of HighCape Capital Acquisition LLC and has voting and investment discretion with respect to the securities held of record by HighCape Capital Acquisition LLC. Mr. Zuga disclaims any beneficial ownership of the securities held by HighCape Capital Acquisition LLC other than to the extent of any pecuniary interest they may have therein, directly or indirectly. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-240283) (the "Registration Statement") and have no expiration date. The shares of Class B common stock beneficially owned by the Reporting Persons include up to 375,000 shares of Class B common stock subject to forfeiture to the Issuer depending on the extent to which the underwriters' over-allotment option is exercised in connection with the Issuer's initial public offering of units, as described in the Registration Statement.
F2: HighCape Capital Acquisition LLC is the record holder of the securities reported herein. Matt Zuga is the sole manager of HighCape Capital Acquisition LLC and has voting and investment discretion with respect to the securities held of record by HighCape Capital Acquisition LLC. Mr. Zuga disclaims any beneficial ownership of the securities held by HighCape Capital Acquisition LLC other than to the extent of any pecuniary interest they may have therein, directly or indirectly.
TELA Bio, Inc.
Report date November 08, 2019 · Filed November 14, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy HighCape Partners, L.P. | 12,675 |
Reported balance
After 2019-11-08 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-11-08 · Purchase · Acquired 10,220 · Balance 12,675 F1: Reflects 2,455 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a). |
| Common StockSEC Table I · non-derivative | IndirectBy HighCape Partners, L.P. | 12,944 |
Reported balance
After 2019-11-13 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2019-11-13 · Conversion · Acquired 269 · Balance 12,944 F3: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. |
| Common StockSEC Table I · non-derivative | IndirectBy HighCape Partners, L.P. | 15,875 |
Reported balance
After 2019-11-13 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2019-11-13 · Conversion · Acquired 2,931 · Balance 15,875 F4: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. |
| Common StockSEC Table I · non-derivative | IndirectBy HighCape Partners QP, L.P. | 260,808 |
Reported balance
After 2019-11-08 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2019-11-08 · Purchase · Acquired 75,901 · Balance 260,808 F2: Reflects 183,907 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a). |
| Common StockSEC Table I · non-derivative | IndirectBy HighCape Partners QP, L.P. | 280,790 |
Reported balance
After 2019-11-13 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2019-11-13 · Conversion · Acquired 19,982 · Balance 280,790 F3: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. |
| Common StockSEC Table I · non-derivative | IndirectBy HighCape Partners QP, L.P. | 498,606 |
Reported balance
After 2019-11-13 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2019-11-13 · Conversion · Acquired 217,816 · Balance 498,606 F4: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy HighCape Partners QP, L.P. | 0 |
Reported balance
After 2019-11-13 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-11-13 · Conversion · Disposed 493,357 · Balance 0 F3: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F5: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy HighCape Partners, L.P. | 0 |
Reported balance
After 2019-11-13 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-11-13 · Conversion · Disposed 6,643 · Balance 0 F3: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F5: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy HighCape Partners QP, L.P. | 0 |
Reported balance
After 2019-11-13 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-11-13 · Conversion · Disposed 5,377,928 · Balance 0 F4: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F5: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy HighCape Partners, L.P. | 0 |
Reported balance
After 2019-11-13 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-11-13 · Conversion · Disposed 72,417 · Balance 0 F4: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F5: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.16 · Expires 2027-01-18 | IndirectBy HighCape Partners QP, L.P. | 0 |
Reported balance
After 2019-11-13 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-11-13 · Conversion · Disposed 123,653 · Balance 0 F6: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.65 · Expires 2027-01-18 | IndirectBy HighCape Partners QP, L.P. | 123,653 |
Reported balance
After 2019-11-13 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2019-11-13 · Conversion · Acquired 123,653 · Balance 123,653 F6: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.16 · Expires 2027-01-18 | IndirectBy HighCape Partners, L.P. | 0 |
Reported balance
After 2019-11-13 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2019-11-13 · Conversion · Disposed 1,665 · Balance 0 F6: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.65 · Expires 2027-01-18 | IndirectBy HighCape Partners, L.P. | 1,665 |
Reported balance
After 2019-11-13 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2019-11-13 · Conversion · Acquired 1,665 · Balance 1,665 F6: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects 2,455 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a).
F2: Reflects 183,907 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a).
F3: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
F4: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
F5: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.
F6: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 13, 2019 Filed Nov 14, 2019 01:57 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionWarrant (right to buy) · Derivative | 1,665 | $0.00 Strike: $28.65 | $0.00 |
DisclosureSEC source: 0001192482-19-000428 · edgar.xml · derivative · entry 14 Zuga Matt · CIK 0001790214 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By HighCape Partners, L.P. Disclosed balance after: 1,665 Underlying: Common Stock · 67 shares Expires 2027-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:57 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionWarrant (right to buy) · Derivative | 1,665 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001192482-19-000428 · edgar.xml · derivative · entry 13 Zuga Matt · CIK 0001790214 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By HighCape Partners, L.P. Disclosed balance after: 0 Underlying: Series B Preferred Stock · 1,665 shares Expires 2027-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:57 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionWarrant (right to buy) · Derivative | 123,653 | $0.00 Strike: $28.65 | $0.00 |
DisclosureSEC source: 0001192482-19-000428 · edgar.xml · derivative · entry 12 Zuga Matt · CIK 0001790214 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By HighCape Partners QP, L.P. Disclosed balance after: 123,653 Underlying: Common Stock · 5,008 shares Expires 2027-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:57 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionWarrant (right to buy) · Derivative | 123,653 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001192482-19-000428 · edgar.xml · derivative · entry 11 Zuga Matt · CIK 0001790214 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By HighCape Partners QP, L.P. Disclosed balance after: 0 Underlying: Series B Preferred Stock · 123,653 shares Expires 2027-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:57 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionSeries B Preferred Stock · Derivative | 72,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000428 · edgar.xml · derivative · entry 10 Zuga Matt · CIK 0001790214 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By HighCape Partners, L.P. Disclosed balance after: 0 Underlying: Common Stock · 2,931 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F4 · derivative.exercise_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F4 · derivative.expiration_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F5 · derivative.underlying_shares: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:57 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionSeries B Preferred Stock · Derivative | 5,377,928 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000428 · edgar.xml · derivative · entry 9 Zuga Matt · CIK 0001790214 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By HighCape Partners QP, L.P. Disclosed balance after: 0 Underlying: Common Stock · 217,816 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F4 · derivative.exercise_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F4 · derivative.expiration_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F5 · derivative.underlying_shares: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:57 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionSeries A Preferred Stock · Derivative | 6,643 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000428 · edgar.xml · derivative · entry 8 Zuga Matt · CIK 0001790214 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By HighCape Partners, L.P. Disclosed balance after: 0 Underlying: Common Stock · 269 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F3 · derivative.exercise_date: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F3 · derivative.expiration_date: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F5 · derivative.underlying_shares: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:57 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionSeries A Preferred Stock · Derivative | 493,357 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000428 · edgar.xml · derivative · entry 7 Zuga Matt · CIK 0001790214 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By HighCape Partners QP, L.P. Disclosed balance after: 0 Underlying: Common Stock · 19,982 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F3 · derivative.exercise_date: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F3 · derivative.expiration_date: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F5 · derivative.underlying_shares: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:57 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionCommon Stock | 217,816 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-19-000428 · edgar.xml · nonDerivative · entry 6 Zuga Matt · CIK 0001790214 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By HighCape Partners QP, L.P. Disclosed balance after: 498,606 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:57 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionCommon Stock | 19,982 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-19-000428 · edgar.xml · nonDerivative · entry 5 Zuga Matt · CIK 0001790214 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By HighCape Partners QP, L.P. Disclosed balance after: 280,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:57 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionCommon Stock | 2,931 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-19-000428 · edgar.xml · nonDerivative · entry 4 Zuga Matt · CIK 0001790214 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By HighCape Partners, L.P. Disclosed balance after: 15,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 01:57 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionCommon Stock | 269 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-19-000428 · edgar.xml · nonDerivative · entry 3 Zuga Matt · CIK 0001790214 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By HighCape Partners, L.P. Disclosed balance after: 12,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| November 08, 2019 Filed Nov 14, 2019 01:57 UTC | TELA Bio, Inc. TELA · Entity 7381 | PurchaseCommon Stock | 75,901 | $13.00 | $986,713.00 |
DisclosureSEC source: 0001192482-19-000428 · edgar.xml · nonDerivative · entry 2 Zuga Matt · CIK 0001790214 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By HighCape Partners QP, L.P. Disclosed balance after: 260,808 F2 · balance_after: Reflects 183,907 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a). Read SEC document |
| November 08, 2019 Filed Nov 14, 2019 01:57 UTC | TELA Bio, Inc. TELA · Entity 7381 | PurchaseCommon Stock | 10,220 | $13.00 | $132,860.00 |
DisclosureSEC source: 0001192482-19-000428 · edgar.xml · nonDerivative · entry 1 Zuga Matt · CIK 0001790214 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By HighCape Partners, L.P. Disclosed balance after: 12,675 F1 · balance_after: Reflects 2,455 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.